KemPharm, Inc. (KMPH) Stock Analysis

KemPharm, Inc. (KMPH) Healthcare & Pipeline Overview

KemPharm, Inc. is a specialty pharmaceutical company leveraging its Ligand Activated Therapy (LAT) platform to develop prodrugs targeting unmet needs in ADHD, stimulant use disorder, and CNS rare diseases. With FDA-approved AZSTARYS and a pipeline of clinical-stage candidates, KemPharm aims to improve drug delivery and efficacy.

What Is the Investment Thesis for KMPH?

KemPharm's investment thesis centers on its proprietary LAT platform's ability to create differentiated prodrugs with improved therapeutic profiles. The company's focus on ADHD, stimulant use disorder, and CNS rare diseases addresses significant unmet medical needs. Key value drivers include the successful clinical development and commercialization of KP1077 for idiopathic hypersomnia and KP879 for stimulant use disorder. AZSTARYS's market penetration and revenue generation are also critical. With a market cap of $200M and a profit margin of 78.2%, KemPharm presents a potentially attractive investment opportunity, contingent on successful clinical trial outcomes and commercial execution. Upcoming clinical trial results for KP1077 represent a significant catalyst. However, potential risks include clinical trial failures and regulatory hurdles.

Based on FMP financials and quantitative analysis

KMPH Key Highlights

Market Cap of $200M indicates the current valuation of the company by the market.

• P/E ratio of 6.56 suggests the company is potentially undervalued compared to its earnings.
• Profit Margin of 78.2% demonstrates strong profitability and efficient operations.
• Gross Margin of 80.7% indicates a high level of efficiency in producing and selling its products.
• Beta of 2.16 suggests the stock is more volatile than the market average.

Who Are KMPH's Competitors?

KMPH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are KMPH's Key Strengths?

Proprietary Ligand Activated Therapy (LAT) platform

• FDA-approved product (AZSTARYS)
• Focus on high-need therapeutic areas
• Strong intellectual property protection

What Are KMPH's Weaknesses?

Limited commercial infrastructure

• Reliance on partners for commercialization
• High research and development costs
• Dependence on clinical trial outcomes

What Could Drive KMPH Stock Higher?

Phase II clinical trial results for KP1077 in idiopathic hypersomnia (IH).

• Continued commercialization and market penetration of AZSTARYS for ADHD.
• Advancement of KP879 through Phase I clinical trials for stimulant use disorder.
• Potential new partnerships and collaborations to expand the pipeline and commercial reach.

What Are the Key Risks for KMPH?

Financial-distress signal — its Altman Z-Score of 1.13 sits in the distress zone (elevated bankruptcy risk).

• Clinical trial failures for KP1077 or KP879.
• Regulatory delays or rejection of drug candidates by the FDA.
• Competition from other pharmaceutical companies in the ADHD, stimulant use disorder, and CNS rare disease markets.
• Patent expiration and generic competition for AZSTARYS.
• Dependence on partners for commercialization and revenue generation.

What Are the Growth Opportunities for KMPH?

• Growth opportunity 1: Successful clinical development and commercialization of KP1077 for the treatment of idiopathic hypersomnia (IH) represents a significant growth opportunity. The IH market is underserved, with limited treatment options available. Positive Phase II trial results could pave the way for Phase III trials and eventual FDA approval. The timeline for potential commercialization is estimated at 3-5 years, with a potential market size of several hundred million dollars annually.
• Growth opportunity 2: Advancing KP879 through clinical trials for the treatment of stimulant use disorder presents another key growth opportunity. The opioid crisis has highlighted the need for effective treatments for addiction. Positive clinical trial results could lead to a significant market opportunity, with a timeline of 4-6 years for potential commercialization. The market size for addiction treatment is substantial and growing.
• Growth opportunity 3: Expanding the market share and revenue generation of AZSTARYS for the treatment of ADHD is crucial for KemPharm's growth. AZSTARYS offers a differentiated profile compared to existing ADHD treatments, potentially capturing a significant portion of the market. Increased marketing efforts and strategic partnerships could drive further adoption. The ADHD market is large and growing, providing ample opportunity for AZSTARYS to gain traction.
• Growth opportunity 4: Exploring new therapeutic applications for KemPharm's LAT platform beyond its current pipeline represents a long-term growth opportunity. The LAT platform can be applied to a wide range of drug candidates, potentially creating new prodrugs with improved properties. Identifying and developing new prodrug candidates could lead to new revenue streams and expand KemPharm's product portfolio. This is an ongoing effort with potential for long-term growth.
• Growth opportunity 5: Strategic collaborations and partnerships with other pharmaceutical companies can accelerate KemPharm's growth and expand its reach. Partnering with companies with established commercial infrastructure and expertise can facilitate the commercialization of KemPharm's products. Collaborations can also provide access to new technologies and resources, further enhancing KemPharm's drug development capabilities. This is an ongoing strategy with potential for near-term and long-term benefits.

What Are KMPH's Competitive Advantages?

• Proprietary Ligand Activated Therapy (LAT) platform
• Patent protection for its prodrug technologies
• FDA approval for AZSTARYS
• Focus on niche therapeutic areas with unmet needs

What Does KMPH Do?

KemPharm, Inc., founded in 2006 and headquartered in Celebration, Florida, is a specialty pharmaceutical company dedicated to discovering and developing proprietary prodrugs to address serious medical conditions within the United States. The company's core technology, Ligand Activated Therapy (LAT), enables the creation of improved prodrug versions of existing FDA-approved drugs, as well as the exploration of new therapeutic applications for existing compounds. This approach aims to enhance drug delivery, improve efficacy, and reduce side effects. KemPharm's product pipeline is strategically focused on high-need areas, including attention deficit hyperactivity disorder (ADHD), stimulant use disorder, and CNS rare diseases, with a particular emphasis on idiopathic hypersomnia (IH). The company's lead product candidate, KP1077, is currently in Phase II clinical trials for the treatment of IH and narcolepsy. KP1077 is based on serdexmethylphenidate, a prodrug of d-methylphenidate. KemPharm is also developing KP879, a prodrug product candidate in Phase I clinical trials for the treatment of stimulant use disorder. Furthermore, KemPharm has achieved FDA approval for AZSTARYS, a once-daily treatment for ADHD in patients aged six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. KemPharm has established collaboration and license agreements with KVK-Tech, Inc. and Commave Therapeutics SA to further its product development and commercialization efforts.

What Products and Services Does KMPH Offer?

• Discovers and develops proprietary prodrugs.
• Utilizes Ligand Activated Therapy (LAT) technology to improve existing drugs.
• Focuses on treatments for ADHD, stimulant use disorder, and CNS rare diseases.
• Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
• Seeks FDA approval for its drug products.
• Commercializes and markets its approved drugs.
• Collaborates with other pharmaceutical companies to expand its reach.

How Does KMPH Make Money?

• Develops and patents proprietary prodrug technologies.
• Out-licenses or co-develops its drug candidates with partners.
• Generates revenue through product sales, licensing fees, and milestone payments.
• Focuses on high-need therapeutic areas with significant market potential.

What Industry Does KMPH Operate In?

KemPharm operates within the biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and significant market potential for innovative therapies. The company's focus on prodrugs aligns with the industry's trend toward developing improved drug formulations with enhanced efficacy and safety profiles. KemPharm competes with other pharmaceutical companies developing treatments for ADHD, stimulant use disorder, and CNS rare diseases. The biotechnology industry is experiencing growth driven by increasing demand for novel therapies and advancements in drug delivery technologies.

Who Are KMPH's Key Customers?

• Patients with ADHD
• Patients with stimulant use disorder
• Patients with CNS rare diseases, such as idiopathic hypersomnia
• Healthcare providers who prescribe KemPharm's medications
• Pharmaceutical companies who partner with KemPharm

Company Profile

KemPharm, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Celebration, US. The company is led by CEO Richard W. Pascoe. KMPH has traded publicly since 2015.

KemPharm, Inc. (KMPH) Valuation Context

Valued at $200M, KMPH is classified as a micro-cap stock.

Return on equity for KemPharm, Inc. stands at 81.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 44.6%, showing how much profit it generates from its asset base. KMPH trades at a trailing price-to-earnings ratio of 6.18, below the Healthcare sector average of ~23x. Its free cash flow yield is 1.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.89 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 16.2%, the inverse of the P/E and a quick read on earnings relative to price.

KemPharm, Inc.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 1.13 places it in the distress zone, a signal of elevated financial risk.

KMPH Financials

KMPH Latest News

No recent news available for KMPH.

Common Questions About KMPH (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources